Update on the Safety and Efficacy of NOAC Therapy for ESUS

Dabigatran is not approved in any country for patients with ESUS
 
In this comprehensive and informative peer-to-peer discussion, Professors Christopher Granger (Duke Clinical Research Institute, US) and David Z Rose (University of South Florida, US) aim to:
  • Help improve the understanding of secondary stroke prevention after Embolic Stroke of Undetermined Source (ESUS).
  • Enable physicians to understand the results of the RESPECT – ESUS trial.
  • Inform physicians of the relevance of the RESPECT – ESUS trial data to clinical practice.
This video is supported by an unrestricted educational grant by Boehringer Ingelheim.